The book deals with orthomolecular medicine and mineral supplements for treatment of cancer. The supporters of megavitamin therapy believe it is the most exciting discovery of the century. The authors also discuss the healing power of integrated food, bees honey, elevating body alkalinity, and oxygen water for defeating malignant tumors.

"Explains why a significant body of scientific research has been largely ignored by cancer research institutions. Hess has clearly demonstrated the valuable role that social scientists can have in offering a neutral perspective on medical research and how it is shaped by cultural bias."
--"Townsend Letter"

"Hess has made a careful study of one of the most intriguing themes that weaves through the recent history of unconventional approaches to cancer. Every researcher, physician, and general reader interested in this field should welcome this important and incisive contribution."
--"Michael Lerner
President, Commonweal, and author of "Choices in Healing"

Growing numbers of cancer patients are exploring diet, food supplements, herbs, and nontoxic immunotherapies like bacterial vaccines as a means of therapy. Yet most cancer research organizations refuse to even evaluate these alternatives. "Can Bacteria Cause Cancer?" argues convincingly that unless this neglected world of alternative therapies is properly scrutinized, the medical Vietnam of the twentieth century may well affect one in two people by the twenty-first century.

David J. Hess investigates one of the great medical mysteries of the twentieth century--the relationship between bacteria and chronic disease. Recently scientists have overturned long-held beliefs by demonstrating that bacterial infections cause many ulcers; they are now reconsidering the role of bacterial infections in other chronic diseases, such as arthritis. Is it possible, Hess asks, that bacteria can contribute to the many other known causes of cancer?

To answer this intriguing question, Hess takes us into the world of alternative cancerresearchers. Maintaining that their work has been actively suppressed rather than simply dismissed, he examines their claims---that bacterial vaccines have led to some dramatic cases of long-term cancer remission--and the scientific potential of their theories. Economic interests and cultural values, he demonstrates, have influenced the rush toward radiation and chemotherapy and the current cul-de-sac of toxic treatments.

More than a medical mystery story, "Can Bacteria Cause Cancer?" is a dramatic case study of the failure of the war on cancer.

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on "Primary Therapy of Early Breast Cancer" as well as "Supportive Care in Cancer" for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for "curing and caring" for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

The volume provides a forum for original peer-reviewed short communications, full-length research and review articles on new research findings and developments on the topic of genetic targets on cancer therapies. As the field is highly important it requires co-operation between research communities from all over the world to share their knowledge and experience in order to move the field forward. Each chapter includes a discussion of the impact of the tumor microenvironment and cancer stem cells and cover current knowledge in this area as it pertains to the disease, including emerging therapy targeting the microenvironment and/or cancer stem cells.

This volume explores data from the applications of molecular biological methods and the applications of recent immunological and cytogenetic methods in Epstein-Barr Virus (EBV) that will offer readers possible new solutions to the unresolved problems in the EBV field. Chapters in this book cover topics such as: viral life cycle, latency, EBV-associated diseases and EBV diagnostics; in vitro methods including organotypic cultures for the analysis of EBV-epithelial cell interactions; identification of the interacting viral and cellular proteins using affinity purification-mass spectrometry methods; 3D telomere FISH; transcription analysis using high-throughput RNA sequencing, qPCR and nuclear run-on assay; analysis of viral and cellular microRNAs; isolation and characterization of exosomes and the assessment of their function; characterization of the viral genome by terminal repeat analysis and sequencing; the use of chromatin immunoprecipitation coupled sequencing (ChIP-Seq) for the analysis of Zta-DNA interactions; epigenetic analysis by bisulfite sequencing and ChIP; novel in vivo models for the study of EBV infection; and how immunological, virological, tissue culture and molecular methods can be combined to yield Good Manufacturing Practice-compliant EBV-specific T cells for the immunotherapy of EBV-associated post-transplant lymphoproliferative diseases (PTLD). Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Epstein Barr-Virus: Methods and Protocols is a valuable resource for anyone who is interested in this fascinating and evolving field.

These proceedings contain the papers selected for presentation at the 23rd Inter- tional Information Security Conference (SEC 2008), co-located with IFIP World Computer Congress (WCC 2008), September 8-10, 2008 in Milan, Italy. In - sponse to the call for papers, 143 papers were submitted to the conference. All - pers were evaluated on the basis of their signi?cance, novelty, and technical quality, and reviewed by at least three members of the program committee. Reviewing was blind meaning that the authors were not told which committee members reviewed which papers. The program committee meeting was held electronically, holding - tensive discussion over a period of three weeks. Of the papers submitted, 42 full papers and 11 short papers were selected for presentation at the conference. A conference like this just does not happen; it depends on the volunteer efforts of a host of individuals. There is a long list of people who volunteered their time and energy to put together the conference and who deserve acknowledgment. We thank all members of the program committee and the external reviewers for their hard work in the paper evaluation. Due to the large number of submissions, p- gram committee members were required to complete their reviews in a short time frame. We are especially thankful to them for the commitment they showed with their active participation in the electronic discussion

Methadone and buprenorphine are the only two opioids that are indicated for the management of both pain and opioid-related drug addiction. Both present unique challenges to the general practitioner and pain specialist, requiring a separate analysis from the rest of the drugs in the same family. Handbook of Methadone Prescribing and Buprenorphine Therapy is an invaluable guide to the safe use of these opioids. Authored by clinical and academic leaders from a variety of settings and backgrounds, this book includes chapters on pharmacology, adverse effects, safe rotation from other opioids, cardiac toxicity, prescribing, pharmacokinetics, equianalgesic dose and replacement therapy. This comprehensive text provides clinicians, researchers, policy-makers and academicians a resource for all the relevant points in methadone prescribing and buprenorphine therapy.

For the first time, the sad story of America's uranium miners and the duplicity of our government is revealed. This expert study examines, in microcosm, the political, legal, social, medical, engineering, and ethical problems that emerged when American leaders developed a nuclear arsenal to contain the Soviet Union without considering the cost this could have on innocent lives. Medical and public health personnel, policymakers and political scientists, lawyers and legal historians, and citizen watchdogs will find this account illuminating. Ball provides the context in the 1940s and 1950s for understanding the Communist hysteria that swept the country and led policymakers to develop risky nuclear technology and to engage in uranium mining and production while assuring Navajo and Mormon miners of their safety. The study analyzes the medical consequences and the etiology of cancer among miners, the politics behind radioactive policy, the miners' long legal battles, and compensatory legislation in 1990. An appendix provides a federal report about three decades of radiation experiences on U.S. citizens. A bibliography points to primary and secondary source material of note.

This work provides a state-of-the art overview on the most relevant aspects of cell polarity. Volume 1 addresses cell polarity and cell migration (front-rear polarity), cell polarity and barrier formation (apico-basal polarity) and neuronal polarity. It particularly focuses on cell polarity at the molecular level and the underlying molecular mechanisms. It also elaborates the common principles and mechanisms that regulate cellular polarization in different cell types and contexts. Both volumes are intended for professors, group leaders and researchers in cell biology as well as medical professionals in the fields of anatomy, cell biology, physiology, pathology and tumor biology.

Based on 30 years of clinical and research experience, backed by a careful assessment of four decades of published data, Dr. Faguet documented in The War on Cancer (Springer 2005), early advances in cancer treatment and patient survival that soon stalled. Ten years later and after an exhaustive analysis of evidence-based data available through 2013 that incorporates 755 references, he reveals the root causes of the stagnation in cancer control, including the role played by major stakeholders and advocates a coordinated national effort, akin to the Apollo program, to unveil the causes of cancer and their mastery. In the interim, Dr. Faguet urges caregivers to manage patients according to the four ethical principles of beneficence, non-maleficence, respect for patients' autonomy and justice especially at the end of life.

This volume presents methods and protocols on modern analysis of steroid receptor and prostate cancer function. Chapters detail androgen, androgen receptor action, anti-androgen enzalutamide, in vitro and in vivo models, imaging, gene fusions, and help facilitate studies with novel drugs including anti-androgens and chemotherapeutics. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Prostate Cancer: Methods and Protocols aims to provide easily reproducible techniques.

Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.

The second edition of this book serves both as an introductory and reference book focusing on the field of metastatic bone disease. Featuring contributions from experts in the field, this volume describes the molecular and cellular mechanisms involved in the formation of bone metastases, presents the newer advances made in the understanding of the clinical picture and symptoms of patients, analyses the role of bone markers in research and clinical practice and deals with all aspects of imaging modalities applied for the detection and evaluation of bone metastases. Moreover, the use of all available treatment methods, such as radiotherapy, surgery and systemic treatments for the management of patients with metastatic bone disease is discussed in detail. Overall this volume presents a thorough overview of all aspects of metastatic bone disease and provides a comprehensive and concise information resource for researchers, oncologists, orthopaedic surgeons and clinicians dealing with patients with metastatic bone disease.

This project follows on the success of the book "25 years of p53", published by Springer in 2006. Since this publication, there have been considerable advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".

This thesis focuses on the development of gold- and non-classical platinum-based anti-cancer agents that display distinctively different anti-cancer mechanisms compared to the commonly used cisplatin. These metal complexes contain N-heterocyclic carbene (NHC) ligands which are able to form strong M-C(NHC) bonds, conferring high stability and favorable lipophilicity, reactivity and binding specificity of metal complexes on biomolecules. The author demonstrates significant advances made in anti-cancer gold(III), gold(I) and platinum(II) complexes. Detailed chemical synthesis, in vitro and/or in vivo anti-cancer activities are clearly presented including: (i) a class of Au(III) complexes containing a highly fluorescent N^N^N ligand and NHC ligand that simultaneously act as fluorescent thiol "switch-on" probes and anti-cancer agents; (ii) a dinuclear gold(I) complex with a mixed diphosphine and bis(NHC) ligand displaying favorable stability and showing significant inhibition of tumor growth in two independent mice models with no observable side effects; and (iii) a panel of stable luminescent cyclometalated platinum(II) complexes exhibiting high specificity to localize to the endoplasmic reticulum (ER) domain, inducing ER stress and cell apoptosis. These works highlight the clinical potential that gold and platinum complexes offer for cancer treatment.

This volume will introduce new terminology to the field of oncology, subdividing it into oncokinetics-the mechanics of the tumor cells as they arise and spread throughout the body-and oncodynamics-the impact of abnormal cues generated by tumors on the physiological functioning of the body. The volume will outline the importance of oncodynamics from both a cancer patient's and a caregiver's perspectives, stressing its significant impact on cancer patient functionality and the opportunity that cancer researchers will have to develop cross-disciplinary interactions and predict potential consequences of tumors and/or treatment.

Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this interesting cytokine might be developed in the future.

This interdisciplinary thesis introduces a systems biology approach to study the cell fate decision mediated by autophagy. A mathematical model of interaction between Autophagy and Apoptosis in mammalian cells is proposed. In this dynamic model autophagy acts as a gradual response to stress (Rheostat) that delays the initiation of bistable switch of apoptosis to give the cells an opportunity to survive. The author shows that his dynamical model is consistent with existing quantitative measurements of time courses of autophagic responses to cisplatin treatment. To understand the function of this response in cancer cells, he has provided a systems biology experimental framework to study quantitative and dynamical aspects of autophagy in single cancer cells using live-cell imaging and quantitative fluorescence microscopy. This framework can provide new insights on function of autophagic response in cancer cells.